Related Experiment Video
Updated: Dec 13, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Remarkable response to abiraterone acetate in castration-resistant prostate cancer patient with aggressive liver
Masahiro Katsui1,2, Takashi Ohigashi1, Takeo Kosaka2
1Department of Urology International University of Health and Welfare Mita Hospital Tokyo Japan.
Introduction:
The number of treatment options for metastatic castration-resistant prostate cancer has increased in recent years. Abiraterone, which selectively inhibits CYP17 in the androgen synthesis pathway, is widely used. Liver metastasis is one of the worst prognostic factors in metastatic castration-resistant prostate cancer. Only a few case reports have shown abiraterone successfully treated the liver metastasis of metastatic castration-resistant prostate cancer.
Case Presentation:
A 62-year-old man with prostate-specific antigen of 16.69 ng/mL was diagnosed with Gleason 8 (3 + 5) poorly differentiated prostate adenocarcinoma. Androgen deprivation therapy and sequential anti-androgen replacement were performed; however, the disease advanced to castration-resistant prostate cancer with liver metastasis. Prior to docetaxel, abiraterone achieved marked improvements in liver metastasis and prostate-specific antigen.
Conclusion:
Metastatic castration-resistant prostate cancer patients with visceral metastasis were excluded from COU-AA-302, which is phase III trial on abiraterone prior to docetaxel. Although docetaxel is the recommended treatment for the visceral metastasis of castration-resistant prostate cancer according to the European Association of Urology guidelines, abiraterone also has potential as a treatment option.
Insights
Abiraterone acetate, a CYP17 inhibitor, shows promise in treating metastatic castration-resistant prostate cancer with liver metastasis. This case report highlights its effectiveness, even in patients with visceral disease, suggesting it as a viable treatment option.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options.
- Abiraterone acetate, a CYP17 inhibitor, is a widely used therapy for mCRPC.
- Liver metastasis is a poor prognostic factor in mCRPC, with limited evidence of abiraterone efficacy.
